145 related articles for article (PubMed ID: 33678794)
1. Hypertension in Patients Hospitalized with COVID-19 in Wuhan, China.
Zhang Y; Sha T; Wu F; Hu H; Chen Z; Li H; Han J; Song W; Huang Q; Zeng Z
Int Heart J; 2021 Mar; 62(2):337-343. PubMed ID: 33678794
[TBL] [Abstract][Full Text] [Related]
2. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
3. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors.
Zhou X; Zhu J; Xu T
Clin Exp Hypertens; 2020 Oct; 42(7):656-660. PubMed ID: 32404011
[TBL] [Abstract][Full Text] [Related]
5. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
[TBL] [Abstract][Full Text] [Related]
6. Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension.
Zhang Z; Wu S; Wang Z; Wang Y; Chen H; Wu C; Xiong L
BMC Infect Dis; 2023 Dec; 23(1):882. PubMed ID: 38110869
[TBL] [Abstract][Full Text] [Related]
7. Influence of angiotensin receptor and converting enzyme blockers therapy in the respiratory outcome of COVID-19 hospitalized patients.
Lima FB; Muniz FWMG; Meneses GC; Bezerra KC; Moreira CN; Aguiar AP; Nascimento JCR; Veras de S Freitas T; de Bruin PFC; Pereira EDB; Daher EF; Oriá RB
Med Clin (Barc); 2024 Feb; 162(4):163-169. PubMed ID: 38000940
[TBL] [Abstract][Full Text] [Related]
8. A retrospective prognostic evaluation using unsupervised learning in the treatment of COVID-19 patients with hypertension treated with ACEI/ARB drugs.
Ge L; Meng Y; Ma W; Mu J
PeerJ; 2024; 12():e17340. PubMed ID: 38756444
[TBL] [Abstract][Full Text] [Related]
9. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Yan H; Valdes AM; Vijay A; Wang S; Liang L; Yang S; Wang H; Tan X; Du J; Jin S; Huang K; Jiang F; Zhang S; Zheng N; Hu Y; Cai T; Aithal GP
Clin Pharmacol Ther; 2020 Dec; 108(6):1185-1194. PubMed ID: 32910830
[TBL] [Abstract][Full Text] [Related]
10. Effects of Antihypertensive Agents on the Clinical Outcome of Hospitalized COVID-19 Patients Concomitant with Hypertension: A Systematic Review and Meta-Analysis.
Liu J; Huang L; Wei W; Bai Y; Chang E; Leng Y
Heart Lung; 2024; 63():78-85. PubMed ID: 37826924
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Russo V; Piccinocchi G; Mandaliti V; Annunziata S; Cimmino G; Attena E; Moio N; Di Micco P; Severino S; Trotta R; Del Guercio M
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375676
[TBL] [Abstract][Full Text] [Related]
12. Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study.
Xiang HX; Fei J; Xiang Y; Xu Z; Zheng L; Li XY; Fu L; Zhao H
BMC Infect Dis; 2021 Feb; 21(1):158. PubMed ID: 33557785
[TBL] [Abstract][Full Text] [Related]
13. Effects of Comorbidities on the Elderly Patients with COVID-19: Clinical Characteristics of Elderly Patients Infected with COVID-19 from Sichuan, China.
Dai SP; Zhao X; Wu JH
J Nutr Health Aging; 2021; 25(1):18-24. PubMed ID: 33367458
[TBL] [Abstract][Full Text] [Related]
14. Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19.
Li J; Wei Q; Li WX; McCowen KC; Xiong W; Liu J; Jiang W; Marin T; Thomas RL; He M; Gongol B; Hepokoski M; Yuan JX; Shyy JY; Xiong N; Malhotra A
Endocr Pract; 2020 Oct; 26(10):1166-1172. PubMed ID: 33471718
[TBL] [Abstract][Full Text] [Related]
15. Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study.
Zhong L; Wu Y; Gao J; Zhang J; Xie Q; He H; Ji J; Liu Z; Wang C; Liu Z
Ann Med; 2021 Dec; 53(1):770-776. PubMed ID: 34080499
[No Abstract] [Full Text] [Related]
16. Racial and Gender-Based Differences in COVID-19.
Kopel J; Perisetti A; Roghani A; Aziz M; Gajendran M; Goyal H
Front Public Health; 2020; 8():418. PubMed ID: 32850607
[TBL] [Abstract][Full Text] [Related]
17. Hypertension and COVID-19: Ongoing Controversies.
Tadic M; Saeed S; Grassi G; Taddei S; Mancia G; Cuspidi C
Front Cardiovasc Med; 2021; 8():639222. PubMed ID: 33681308
[TBL] [Abstract][Full Text] [Related]
18. A Prediction Model for Assessing Prognosis in Critically Ill Patients with Sepsis-associated Acute Kidney Injury.
Hu H; Li L; Zhang Y; Sha T; Huang Q; Guo X; An S; Chen Z; Zeng Z
Shock; 2021 Oct; 56(4):564-572. PubMed ID: 33847475
[TBL] [Abstract][Full Text] [Related]
19. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
Galan LEB; Santos NMD; Asato MS; Araújo JV; de Lima Moreira A; Araújo AMM; Paiva ADP; Portella DGS; Marques FSS; Silva GMA; de Sousa Resende J; Tizolim MR; Santos PL; Buttenbender SF; de Andrade SB; Carbonell RCC; Da Rocha JG; de Souza RGS; da Fonseca AJ
Pathog Glob Health; 2021 Jun; 115(4):235-242. PubMed ID: 33682640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
